CORTICOSTEROID AND THYROID EFFECTS ON LUNG MATURATION

NIH RePORTER · NIH · R01 · $110,215 · view on reporter.nih.gov ↗

Abstract

We are seeking continued funding to ask a number of questions about strategies to mature the fetal lung that have the potential to be applied clinically. We hypothesize that single dose, direct fetal administration of hormones alone or in combination will cause rapid and large lung maturational effects in fetuses that have not been previously manipulated. We plan to use hormones (corticosteroids, thyroid hormones, EGF and TGF-alpha) only at doses and treatment durations that are clinically relevant. We will treat preterm sheep by ultrasound guided direct fetal injections and then deliver the preterm lambs 48 hours later. The lambs will be evaluated extensively for postnatal pulmonary adaptation over 4 hours. Physiologic assessments will focus on measurements that translate into improved lung function. We will measure lung volumes, compliances, gas exchange, edema formation, and the responses of the lungs to surfactant treatment. We also will measure biochemical markers of lung maturation - alveolar and lung tissue saturated phosphatidylcholine pool sizes, alveolar surfactant protein A (SP-A), and SP-A, SP-B, and SP-C mRNA levels in lung tissue. The goal is to identify a simple, single dose treatment strategy that can include agents not permeable to the placenta that will effectively and reliably mature the fetal lung.

Key facts

NIH application ID
2198052
Project number
5R01HD020618-09
Recipient
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
SAM.gov UEI
LTJVF4QSFCP9
Principal Investigator
Michael Glenn Ross
Activity code
R01
Funding institute
NIH
Fiscal year
1994
Award amount
$110,215
Award type
5
Project period
1985-09-01 → 1996-11-30